Freepik.comAntibodyThis Memo sticks: CSL bites in Switzerland for antibody collaborationThe Australian–Swiss plasma specialist CSL is relying on technology from Switzerland for recombinant polyclonal immunoglobulins (IgG). With Memo Therapeutics, the company has entered into a collaboration … more ➔
financing4Moving Biotech raises €12m to prove whether GLP-1 can crack osteoarthritisAfter more than a decade of failed drug development efforts, osteoarthritis remains one of biopharma’s most stubborn challenges. Despite affecting more than 600 million people worldwide, no therapy … more ➔
© Bayer LeverkusenStrokeBayer: At last, success with coagulation factor XIa in phase 3 stroke trialBayer can report a success in stroke treatment, even though an earlier study with the same compound had been discontinued due to limited benefit. The approach of inhibiting factor XIa represents a first-in-class … more ➔
FundraisingDublin-based Aerska secures $39M Series A to push RNA medicines into the brainAerska, a biotechnology company focused on RNA medicines for brain diseases, has raised €32 million in a Series A financing to advance its lead technology toward clinical development. The round was … more ➔
Real estateU.K. life sciences infrastructure gets a boost as London and Cambridge expandTwo of the U.K.’s largest life sciences real-estate projects have moved forward within days of each other, with major expansion plans unveiled in London and Cambridge as both regions look to add new … more ➔
RoyaltiesBioArctic is cashing in on Eisai and Biogen growing sales in Alzheimer’s diseaseStockholm-based BioArctic is receiving SEK 127 million (about €11.9 million at today’s exchange rate) in royalties from the Alzheimer’s disease therapy Leqembi (lecanemab). more ➔
IPOAgomab goes public on Nasdaq as biotech IPOs top $1bn in a single weekJust three weeks after announcing its plans for a U.S. listing, Belgium-based Agomab has gone public on Nasdaq after pricing its IPO at $16 per share, aiming to bring in about $200 million in gross proceeds … more ➔
adobe stock photos - Michael Derrer Fuchs NovartisNovartis celebrates strong profits, while the CEO enjoys record pay triggering discussionNovartis increased its annual profit in 2025 to USD 17.4 billion and raised its dividend. Towards the end of the year, however, growth weakened markedly, weighed down by copycat products. The group has … more ➔
clinical dataLeyden Labs reports first human data for intranasal flu prevention antibodyLeyden Labs has released new early-stage data on its intranasal antibody program for influenza prevention, adding phase 1 human safety results to previously disclosed animal studies. more ➔
chokniti - Adobe StockRadiopharmacyPentixapharm: positive Phase II data on Pentixafor PET diagnostics pave way for radiotherapeuticsPentixapharm Holding AG published new clinical Phase II data on its radiodiagnostic agent [68Ga]Ga-Pentixafor in early February. As the Berlin-based company reported, the results published in the Journal … more ➔
Freepik.com
© Bayer Leverkusen
adobe stock photos - Michael Derrer Fuchs 
chokniti - Adobe Stock